Creative Biolabs Wishes a Deeper and Further Dive into Immunology in 2023
Creative Biolabs is a CRO dedicated to biotechnology advancement, mainly providing services and products supportive of new drug discovery and disease research. The company wishes to dig deeper into the area and further extend its capabilities in immunology, hoping to serve more client projects and overcome obstacles hindering clients' journey to success.
New York, NY (PRUnderground) November 23rd, 2022
“It has been almost three years since the outbreak of COVID-19,” according to one of the specialists at Creative Biolabs, “which seems to be the most devastating threat to the entire health community in recent decades. Even though in most continents, it is no longer recognized as a panic, steps towards discovering effective treatment options never halt, and we cannot let our guard down as there are emerging pathogens coming up every day. It’s our role to help discover effective solutions.”
Creative Biolabs is a CRO that always sticks to the battlefront, providing support for new drug discovery and disease studies. The company sets foot in multi-facets of biomedicine discoveries, especially using its expertise in antibody, chemical conjugation, and vaccine design.
For virus diseases like COVID-19, Creative Biolabs typically utilized its viral antibody discovery solution center, which offers antibody products that are readily available for shipment and were developed against hot research targets, such as the spike protein of SARS-CoV-2.
“Aside from our expertise in antibodies, we can also be the strong endorsement of your vaccine project.” Added the specialist. Creative Biolabs is renowned for its expertise in vaccine design, vaccine formulation optimization, validation, and five-star vaccine design raw materials, including adjuvants, antigens, and delivery systems. Not to mention Creative Biolabs’ most welcomed part lies in the oncology vaccine, which established a one-stop service workflow covering design all the way to validation for cancer vaccine candidates.
Another specialization of the company regards its innovative conjugates, which have attracted increasing attention these years due to their outstanding targeting capabilities toward cancer cells.
“We’re working on novel conjugates,” commented the specialist, “utilizing knowledge of ADC conjugation chemistry and technology platforms. One example is antibody-oligonucleotide conjugates, a novel class of synthetic chimeric biomolecules that is gaining traction in various fields of modern biotechnology.”
In 2022, Creative Biolabs has participated in many global events concerning antibody discovery and engineering, immuno-oncology subjects, ADC, bispecific antibodies, etc., hoping to expose its capabilities in biotech fields to more researchers on a worldwide scale.
“We hope that through those events, where we played the role of an exhibitor, we can let more people know that we are working hard in the field, and our strategies and products can help accelerate the research progress together. We’re hoping to dive more deeply and thoroughly into immunology and disease therapy in 2023 through communicating with researchers and future projects.”
Learn more about Creative Biolabs at https://www.creative-biolabs.com/.
About Creative Biolabs
Creative Biolabs provides solutions regarding new drug discovery and has special expertise in antibody development and immunotherapy discovery. To showcase its service capabilities, Creative Biolabs will participate in Antibody Engineering & Therapeutics US 2022 in December 2022.